Nele Festjens and Nico Callewaert of VIB and Ghent University have improved the efficacy of the vaccine for tuberculosis. The new vaccine affords -- as already proven in mice -- better protection against the disease. The development of a new tuberculosis vaccine is a priority in the fight against the disease which claims the lives of 1.7 million people each year. The current vaccine provides only partial protection. VIB is a non-profit research institute in the life sciences in Flanders, Belgium, with 1,200 scientists conducting strategic basic research on the molecular mechanisms that are responsible for the functioning of the human body, plants and microorganisms.
"Our vaccine is more effective because it is more quickly recognized by the immune system of the vaccinated person. We have, as it were, undressed the existing vaccine by removing its protective shield," Callewaert says.
One-third of the world population is infected with the Mycobacterium tuberculosis bacterium which causes tuberculosis (TB). TB, AIDS and malaria are the three infectious diseases claiming the largest number of fatalities worldwide. The World Health Organization (WHO) estimates that each year 8 million to 10 million people become infected. TB is in particular a disease of the poor and mainly affects young adults in their most productive years. Most TB fatalities are in the developing countries, more than half of them in Asia. In almost all of these countries, multidrug-resistant TB is becoming increasingly frequent. This form of TB is very hard to treat.
TB treatments are expensive and also very difficult because of multidrug-resistant TB. There has therefore been a strong focus on vaccination in the fight against TB. The only vaccine on the market is Bacillus Calmette-GuÃ©rin (BCG). It is produced from attenuated live bovine tuberculosis bacterium, Mycobacterium bovis, which has lost its virulence in humans. In children, the vaccine prevents only half of cases of tuberculosis and in adolescents and adults the degree of protection is much lower still.
In recent years, several other candidate vaccines have been developed and some of these have been tested on humans. Only a few have led to a moderate improvement in protection compared with the BCG vaccine. The search for a more efficient vaccine is therefore still on.
The bacterium from which the BCG vaccine is derived hides as it were from the immune system of the organism in which it ends up. This may well be the reason why the vaccine is not very effective. The fact is that a vaccine is meant to trigger an immune reaction in order to be able to afford good protection. Nele Festjens and Nico Callewaert have discovered that the bacterium hides behind the SapM enzyme that acts as a kind of shield.
They have used this knowledge to develop a new vaccine. They adapted Mycobacterium bovis BCG in such a way that it was no longer able to generate SapM and could therefore no longer hide from the immune system. Testing the new vaccine on mice has shown that it affords better protection than the present BCG vaccine.
The researchers also demonstrated that their vaccine works in a way different from the other vaccines currently being tested. In fact, it acquires its extra protective value by emitting signals that provoke inflammation and in this way activate the right cells of the immune system. Festjens and Callewaert are convinced that applying their strategy - removing the protective shield - in the new vaccines that are somewhat better than the vaccine currently being marketed should lead to a vaccine that affords genuine protection against TB.
The study is reported in the journal EMBO Mol. Med (Festjens et al., Disruption of the SapM locus in Mycobacterium bovis BCG improves its protective efficacy as a vaccine against M. tuberculosis)
This study has partly been funded by the Marie Curie Excellence Grant (EU FP6), Methusalem, FWO, UGent and VIB.
The study was conducted by Nele Festjens and colleagues under the direction of Nico Callewaert at the VIB Department for Molecular Biomedical Research, UGent. In collaboration with Dr. Kris Huygen from the Scientific Institute of Public Health.